Euclises Pharmaceuticals, Inc., a St. Louis-based biotechnology company developing novel COX-2 inhibitors for the treatment of cancer, closed $1.3m Series A financing.
The round was led by Cultivation Capital, with participation from BioGenerator, Missouri Technology Corporation, ABC Laboratories, the St. Louis County Port Authority’s Helix Fund and the St. Louis Arch Angels. In conjunction with the funding, Charles Bolten from BioGenerator, Robert Calcaterra, Ph.D., President of the St. Louis Arch Angels, and Robert Beardsley, Ph.D., Executive Chair at Galera Therapeutics, Inc., joined Euclisis’ board.
The company intends to use the funds to prepare its Euclicoxib® product candidates for clinical trials in cancer patients.
Led by John Talley, Ph.D., CSO and inventor of celecoxib, and Rajesh Devraj, Ph.D., CEO, Euclises focused on novel cyclooxygenase-2 (COX-2) inhibitors for use in the oncology setting. The company has developed a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. It is currently headquartered within the BioGenerator Accelerator Labs at CORTEX.